<DOC>
	<DOCNO>NCT02354534</DOCNO>
	<brief_summary>This phase I research protocol design assess immunogenicity clinical endpoint patient HPV16 CIN2/3 . The protocol test use artesunate suppository formulation apply intravaginally patient cervical dysplasia ( CIN2/3 ) . The primary endpoint determine evaluate safety , tolerability , feasibility intravaginal administration artesunate health woman CIN2/3 .</brief_summary>
	<brief_title>Intravaginal Artesunate Treatment HPV+ High Grade Cervical Intraepithelial Neoplasia ( CIN2/3 )</brief_title>
	<detailed_description>Phase I open-label dose escalation study intravaginal artesunate , formulate suppository , adult female biopsy-confirmed CIN2/3 . Thirty ( 30 ) subject undergo total three cycle intravaginal artesunate . The first cycle initiate Day 0 , second Week 4 , third final cycle week 8 .</detailed_description>
	<mesh_term>Neoplasms</mesh_term>
	<mesh_term>Carcinoma Situ</mesh_term>
	<mesh_term>Cervical Intraepithelial Neoplasia</mesh_term>
	<mesh_term>Uterine Cervical Dysplasia</mesh_term>
	<mesh_term>Artesunate</mesh_term>
	<mesh_term>Artemisinins</mesh_term>
	<criteria>≥ 18 year Capable informed consent HPVpositive DNA test Histologically confirm CIN2 , CIN3 , CIN2/3 Body weight ≥ 50 kg Immune competent Pregnant nursing woman HIV seropositive Active autoimmune disease Taking immunosuppressive medication Evidence concurrent adenocarcinoma situ Concurrent malignancy except nonmelanoma skin lesion</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>cervical dysplasia</keyword>
	<keyword>HPV</keyword>
	<keyword>Treatment</keyword>
	<keyword>preinvasive</keyword>
	<keyword>cervix</keyword>
	<keyword>vaginal suppository</keyword>
	<keyword>Johns Hopkins</keyword>
	<keyword>Cornelia Trimble</keyword>
	<keyword>abnormal pap</keyword>
	<keyword>CIN</keyword>
</DOC>